Lately, prophylactic bilateral mastectomy has to be offered more and more frequently due to the increased detection of patients carrying a genetic mutation or predisposition to develop breast cancer (e.g., BRCA-1, BRCA-2, p53). Here, TP53 is linked to breast carcinoma.